Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 6/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | ACE | P12821 | 2/20 | 0.62 |
| ▸ | CTSB | P07858 | 2/20 | 0.61 |
| ▸ | CTSL | P07711 | 2/20 | 0.59 |
| ▸ | CTSS | P25774 | 2/20 | 0.59 |
| ▸ | CTSK | P43235 | 2/20 | 0.59 |
| ▸ | CTSV | O60911 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.56 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4798353 | 1.00 | GPR132 (0.65) | GPR132L3MBTL1ACECTSBCTSL | |
| SCHEMBL9830977 | 0.92 | CTSB (0.72) | GPR132L3MBTL1ACECTSBCTSL | |
| SCHEMBL28944420 | 0.90 | L3MBTL1 (0.59) | GPR132L3MBTL1ACECTSBCTSL | |
| SCHEMBL5841030 | 0.90 | ALB (0.55) | GPR132L3MBTL1ACECTSBCTSL | |
| SCHEMBL18292346 | 0.89 | HPGDS (0.70) | GPR132L3MBTL1CTSBCTSLCTSS | |
| SCHEMBL8724859 | 0.89 | L3MBTL1 (0.63) | GPR132L3MBTL1ACECTSBCTSL | |
| SCHEMBL8724861 | 0.89 | L3MBTL1 (0.63) | GPR132L3MBTL1ACECTSBCTSL | |
| SCHEMBL23279720 | 0.89 | CTSL (0.57) | GPR132L3MBTL1ACECTSBCTSL | |
| SCHEMBL23279723 | 0.89 | CTSL (0.57) | GPR132L3MBTL1ACECTSBCTSL | |
| SCHEMBL4180329 | 0.88 | ALDH1A1 (0.67) | GPR132L3MBTL1CTSBCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | DEWIS MARK L | 2009-02-19 | — | — | US | disclosed |
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | DEWIS MARK L | 2009-02-19 | — | — | US | disclosed |
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | DEWIS MARK L | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | TAS2R10, TAS2R50, TAS2R8 | GPR132 246/4885L3MBTL1 4231/4885ACE 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.